Effectiveness of a Guideline for Venous Thromboembolism Prophylaxis in Elderly Post–Acute Care Patients

A Multicenter Study With Systematic Ultrasonographic Examination

Elodie Sellier, MD; Jose Labarere, MD; Jean-Luc Bosson, MD, PhD; Malika Auvray, MD; Marie-Therese Barrellier, MD; Claire Le Hello, MD; Joel Belmin, MD, PhD; Philippe Le Roux, MD; Marie-Antoinette Sevestre, MD, MSc; for the Association pour la Promotion de l’Angiologie Hospitalière

Background: Thromboprophylaxis in elderly patients, including post–acute care patients, is at variance with scientific evidence. The purpose of this study was to determine whether a multifaceted intervention was followed by a decrease in deep venous thrombosis (DVT).

Methods: A prospective preintervention-postintervention study was conducted in 1373 patients (preintervention phase, n=709; postintervention phase, n=664), aged 65 years or older, enrolled in 33 hospital-based post–acute care facilities in France. An evidence-based guideline addressing pharmacologic and mechanical prophylaxis was implemented through a multifaceted intervention. The main outcome measure was any DVT diagnosed at routine comprehensive ultrasonography performed by registered angiologists.

Results: A DVT was found in 91 patients (12.8%) in the preintervention phase and in 52 patients (7.8%) in the postintervention phase (P=.002). The decrease in DVT involved the calf (7.1% vs 3.6%; P=.005) and the proximal venous segments (5.8% vs 4.2%; P=.18) and remained significant after adjusting for risk factors (adjusted odds ratio of any DVT, 0.58; 95% confidence interval, 0.39-0.86). Pharmacologic prophylaxis with either low-molecular-weight heparin at the high-risk dose, unfractionated heparin, and vitamin K antagonist was similar in the 2 study groups, whereas patients in the postintervention group were more likely to use graduated compression stockings (27.4% vs 34.6%; P=.004) and less likely to receive low-molecular-weight heparin at the low-risk dose (24.7% vs 18.5%; P=.006), which was not recommended by our guideline.

Conclusions: A multifaceted intervention addressing venous thromboembolism prophylaxis in post–acute care patients can be followed by a significant decrease in the rate of any DVT in elderly patients. More active interventions are needed to enforce compliance with evidence-based guidelines.

Arch Intern Med. 2006;166:2065-2071
The purpose of this study was to assess the effectiveness and safety of this clinical practice guideline on venous thromboembolism (VTE) prophylaxis in post–acute care patients. Using a preintervention-postintervention study design, we hypothesized that a multifaceted intervention to implement our guideline would be associated with more appropriate use of prophylaxis and a decreased rate of DVT without compromising patient safety.

STUDY DESIGN

We conducted a prospective preintervention-postintervention study in 33 hospital-based post–acute care facilities in France. Of the participating facilities, 17 were located in teaching hospitals; 25 were skilled nursing facilities, and 8 were rehabilitation facilities. Inclusion criteria, data collection forms, and the ultrasonographic diagnostic procedure were similar for the 2 study phases. All enrolled patients provided written informed consent.

PRACTICE GUIDELINE

Our practice guideline for VTE prophylaxis in post–acute care patients was based on a systematic review of the literature and the results of a cross-sectional study and was developed using group consensus of expert panelists (listed in Bosson et al). All recommendations were approved by physicians at participating post–acute care departments before implementation of the intervention. The guideline also was approved by the French Vascular Medicine Society and the French Geriatrics Society. In brief, the guideline recommended pharmacologic prophylaxis for up to 6 weeks after hip or knee replacement or other major surgical procedure; until discharge in patients with pulmonary embolism or proximal DVT within the previous 2 years; and for 1 week or longer, depending on the persistence of the risk factors, in patients with 2 or more risk factors such as recent immobility, VTE at other sites, hemiplegia, cancer, acute infectious disease, acute heart failure, acute respiratory failure, and myocardial infarction. Pharmacologic prophylaxis was recommended with either low-molecular-weight heparin (LMWH) at the usual high-risk dose (ie, dalteparin sodium, 5000 U/d; enoxaparin sodium, 4000 U/d; nadroparin calcium, 2850 U/d; and tinzaparin sodium, 4500 U/d), adjusted-dose vitamin K antagonist, or unfractionated heparin. Prophylaxis with LMWH at the low-risk dose was not recommended because there was no evidence that it performed better than placebo in preventing VTE in a broad spectrum of medical patients. Prophylaxis with unfractionated heparin, 5000 U per 12 hours, rather than LMWH was recommended in patients with creatinine clearance of 30 mL/min (0.50 mL/s) or less. We advocated the use of the Cockroft-Gault equation for computing creatinine clearance. Our guideline also addressed mechanical prophylaxis including GCS use, early ambulation, and physical therapy. Graduated compression stockings (15-20 mm Hg) were recommended for use during daytime hours or longer, alone or in combination with pharmacologic prophylaxis, in immobilized patients until they recovered ambulation.

STUDY INTERVENTION

We implemented a multifaceted intervention directed at physicians and nurses in every participating department. The intervention included an educational presentation, dissemination of educational material, and audit-feedback components.

DATA COLLECTION

Trained physicians independent of those in charge of the patients prospectively investigated transient and chronic risk factors for DVT (Table 1) and prophylaxis using a standardized data abstract form. For each patient, we retrospectively computed a DVT risk score using the risk factors and corresponding weights that composed the revised rule proposed by Wells et al. Data on prophylaxis with LMWH, unfractionated heparin, vitamin K antagonist, and GCS were investigated by reviewing physicians’ orders and medical records. Compliance with GCS use was assessed by direct observation on the day compression ultrasonography was performed. We defined GCS users as patients who wore below-knee or thigh-high GCS during daytime hours or longer. Although we assessed stocking length, daily duration of use, and overall duration of use, we could not document correct sizing, application, and monitoring of GCS.

STUDY OUTCOMES

Our primary outcome was any DVT detected at routine ultrasonography on the day of a cross-sectional study. All patients underwent comprehensive compression ultrasonography performed by registered vascular medicine physicians (J.-L.B., M.-T.B., C.L.H., P.L.R., and M.-A.S.) who were unaware of both risk factors and thromboprophylaxis. As described, all deep veins of the lower limbs were examined from the inguinal ligament to the malleolus using a 3- to 7.5-MHz transducer. Only incompressible veins with a thrombus 5 mm or larger in anteroposterior diameter were considered positive for DVT. Deep vein thromboses were categorized as proximal (thigh or popliteal segments) or distal (calf segments). Isolated muscular vein thromboses (ie, gastrocnemius or soleal vein thromboses) were not considered DVTs.

We also investigated secondary outcome measures, including major and minor bleeding and thrombocytopenia, to assess the safety of our intervention. Thrombocytopenia was defined as platelet count less than 100 × 10^9/L. Platelet count was ordered at the discretion of physicians in charge of the patients.
SAMPLE SIZE

Based on the findings of a previous study,1,2 we hypothesized that the prevalence of any DVT would be 15% in the preintervention phase. Assuming a power of 80% and a statistical significance level of .05, we estimated that 727 patients enrolled in each study phase would be enough to evidence a 30% relative reduction in the rate of any DVT (ie, from 15% in the preintervention phase to 10% in the postintervention phase).

STATISTICAL ANALYSIS

Categorical variables were expressed as frequencies and percentages, and continuous variables as median and interquartile range. Differences in baseline characteristics for patients in the preintervention and postintervention groups were compared using χ² or Fisher exact tests when appropriate for categorical variables and the Wilcoxon rank sum test for continuous variables. We estimated the odds ratio (OR) of any DVT and its associated 95% confidence interval for patients in the postintervention phase compared with those in the preintervention phase using univariable logistic regression. An OR lower than 1 meant that patients in the postintervention group were at decreased risk for any DVT. In multivariable analysis, we developed a logistic regression model adjusting for sex, age, transient and chronic risk factors, and post–acute care department characteristics. Ten patients with missing data for 1 covariate or more were excluded from multivariable analysis. We used a 2-level logistic regression model to account for patients clustering within post–acute care departments. P≤.05 was considered statistically significant. Analyses were performed using STATA version 9.0 (StataCorp, College Station, Tex) and MLWin 2.0 (Institute of Education, London, England).

RESULTS

Of the 1804 patients screened for eligibility, 431 (23.9%) were excluded for the following reasons: long-term anticoagulant therapy with heparin or an oral anticoagulant agent for reasons other than VTE prophylaxis (136 patients), age younger than 65 years (135 patients), positive diagnosis of DVT or pulmonary embolism at hospital admission (81 patients), and refusal to participate (79 patients). Of eligible patients, 709 were enrolled in the preintervention phase and 664 were enrolled in the postintervention phase, with a median number of patients enrolled per department of 22 (interquartile range, 15-28) and 19 (interquartile range, 11-26), respectively (P=.29).

Table 1. Baseline Characteristics in Elderly Post–Acute Care Patients in the Preintervention and Postintervention Groups*

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Preintervention (n = 709)</th>
<th>Postintervention (n = 664)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, median (IQR), y†</td>
<td>82 (77-88)</td>
<td>82 (77-89)</td>
<td>.22</td>
</tr>
<tr>
<td>Female sex†</td>
<td>486 (69)</td>
<td>432 (65)</td>
<td>.20</td>
</tr>
<tr>
<td>Chronic risk factors for venous thromboembolism</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute immobility &lt;30 d</td>
<td>113 (15.9)</td>
<td>97 (14.6)</td>
<td>.49</td>
</tr>
<tr>
<td>Hip or knee replacement &lt;6 wk</td>
<td>100 (14.1)</td>
<td>56 (8.4)</td>
<td>.001</td>
</tr>
<tr>
<td>Major surgery &lt;4 wk</td>
<td>62 (8.7)</td>
<td>85 (12.8)</td>
<td>.01</td>
</tr>
<tr>
<td>Stroke &lt;4 wk</td>
<td>10 (1.4)</td>
<td>16 (2.4)</td>
<td>.18</td>
</tr>
<tr>
<td>Acute respiratory failure or exacerbation of COPD</td>
<td>30 (4.2)</td>
<td>22 (3.3)</td>
<td>.37</td>
</tr>
<tr>
<td>NYHA class III or IV congestive heart failure</td>
<td>13 (1.8)</td>
<td>17 (2.6)</td>
<td>.36</td>
</tr>
<tr>
<td>Acute infectious disease</td>
<td>65 (9.2)</td>
<td>64 (9.6)</td>
<td>.77</td>
</tr>
<tr>
<td>Transient risk factors for venous thromboembolism</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prolonged immobility ≥30 d</td>
<td>221 (31.2)</td>
<td>242 (36.4)</td>
<td>.04</td>
</tr>
<tr>
<td>History of DVT or pulmonary embolism</td>
<td>82 (11.6)</td>
<td>55 (8.3)</td>
<td>.04</td>
</tr>
<tr>
<td>Hemiplegia ≥4 wk</td>
<td>64 (9.0)</td>
<td>49 (7.4)</td>
<td>.27</td>
</tr>
<tr>
<td>Cancer</td>
<td>70 (9.9)</td>
<td>97 (14.6)</td>
<td>.007</td>
</tr>
<tr>
<td>Chronic respiratory failure or COPD</td>
<td>29 (4.1)</td>
<td>57 (8.6)</td>
<td>.001</td>
</tr>
<tr>
<td>Chronic heart failure</td>
<td>87 (12.3)</td>
<td>135 (20.3)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Varicose veins</td>
<td>115 (16.2)</td>
<td>105 (15.8)</td>
<td>.84</td>
</tr>
<tr>
<td>Hormone therapy</td>
<td>8 (1.1)</td>
<td>17 (2.6)</td>
<td>.05</td>
</tr>
<tr>
<td>Inflammatory disorder‡</td>
<td>18 (2.5)</td>
<td>19 (2.9)</td>
<td>.71</td>
</tr>
<tr>
<td>History of myocardial infarction</td>
<td>24 (3.4)</td>
<td>43 (6.5)</td>
<td>.008</td>
</tr>
<tr>
<td>Obesity§</td>
<td>74 (10.4)</td>
<td>56 (8.4)</td>
<td>.21</td>
</tr>
<tr>
<td>Risk score for DVT</td>
<td></td>
<td></td>
<td>.59</td>
</tr>
<tr>
<td>0</td>
<td>198 (27.9)</td>
<td>192 (28.9)</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>378 (53.3)</td>
<td>339 (51.1)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>120 (16.9)</td>
<td>119 (17.9)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>13 (1.8)</td>
<td>12 (1.8)</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>0</td>
<td>2 (0.3)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: COPD, chronic obstructive pulmonary disease; DVT, deep venous thrombosis; IQR, interquartile range; NYHA, New York Heart Association.

*Data are given as number (percentage) unless otherwise indicated.
†Data on age and sex were missing for 10 patients.
‡Inflammatory disorders included arthritis, connective tissue disease, and inflammatory bowel disease.
§Obesity was defined as body mass index (calculated as weight in kilograms divided by height in meters squared) of 30 or higher in men and 28.6 or higher in women.
| (REPRINTED) ARCH INTERN MED/VOL 166, OCT 23, 2006 WWW.ARCHINTERNMED.COM | ©2006 American Medical Association. All rights reserved.
The median age of the patients was 82 years (interquartile range, 77-88), and 66.9% of all patients were women. Patients in the postintervention group were more likely to have prolonged immobility, recent major surgery, cancer, chronic respiratory failure or chronic obstructive pulmonary disease, chronic heart failure, and history of myocardial infarction, whereas those in the preintervention group were more likely to have recent hip or knee replacement surgery and a history of VTE. Overall, the preintervention and postintervention patient groups had a comparable DVT risk score at hospital admission (Table 1).

The percentages of patients receiving pharmacologic prophylaxis with either LMWH at the high-risk dose, unfractionated heparin, or vitamin K antagonist were comparable for the preintervention and postintervention groups, whereas patients in the postintervention group were more likely to use GCS and less likely to receive LMWH at the low-risk dose, which was not recommended by our guideline (Table 2). The increased use of GCS was observed in patients in whom pharmacologic prophylaxis was not recommended (Table 2) but mechanical prophylaxis was recommended (Table 3) according to our guideline. The decrease in the use of LMWH at the low-risk dose involved patients in whom pharmacologic prophylaxis was not recommended (Table 3).

The median day on which patients underwent compression ultrasonography was not different for the preintervention and postintervention groups (21 vs 22; P = .25). Deep venous thrombosis was found in 91 patients (12.8%) in the preintervention group and in 52 (7.8%) in the postintervention group (OR, 0.58; 95% confidence interval, 0.40-0.83; P = .002). The decrease in thrombosis involved all venous segments of the lower limbs, although it was not significant for the proximal veins (Figure). In multivariable analysis, the decreased odds of DVT in patients in the postintervention group remained significant after adjusting for baseline patient and facility characteristics (adjusted OR, 0.58; 95% confidence interval, 0.39-0.86; P = .007). Considering safety outcomes, no major bleeding was documented, and the rates of minor bleeding (0.7% vs 1.0%; P = .49) and thrombocytopenia (0.8% vs 0.1%; P = .12) were not different in the preintervention and postintervention groups, respectively.

In this prospective multicenter study, a multifaceted intervention designed to implement an evidence-based guideline addressing VTE prophylaxis after acute care was followed by a reduction in DVT without compromising patient safety. These findings are consistent with those of previous studies. In a clustered, randomized, controlled trial, Anderson et al demonstrated that a formal continuous medical education program increased the use of both pharmacologic and mechanical prophylaxis in inpatients who required acute care. However, the authors did not investigate whether their intervention was followed by a reduction in DVT. Using the same study design as in the present study, we previously reported a significant decrease in the rate of any DVT after the implementation of a multifaceted intervention directed at all medical providers involved in VTE prophylaxis in acutely ill medical inpatients. Our findings are also supported by randomized controlled trials that demonstrated that multifaceted intervention can change professional practice and health care outcomes.

Changes in the prophylaxis means measured can only partly explain the decrease in the rate of DVT observed in our study. The most important change in prophylaxis consisted of an increased use of GCS, while the change in pharmacologic prophylaxis use was modest and not statistically significant. The apparent failure of our intervention to alter the rate of pharmacologic prophylaxis may have several potential explanations. First, the baseline rate of pharmacologic prophylaxis use (33% for all patients and 43% for patients in whom prophylaxis was recommended according to our guideline) was relatively high compared with previous studies, and a more intensive intervention would have been necessary to further increase this rate. Second, physicians were likely reluctant to order pharmacologic prophylaxis in this setting because they feared patient bleeding. Third, evidence of the efficacy of prolonged pharmacologic prophylaxis is lacking, although some studies indirectly suggest it may be necessary in medical inpatients at high risk. Another important finding of our study was the significant decrease in the rate of prophylaxis with LMWH at the low-risk dose, which reflected physician compliance with our guideline. These observations together suggest that our multifaceted intervention not only altered the use of measured prophylaxis means but also improved physician and nurse awareness of patients at risk for VTE and eventually increased the use of additional prophylactic measures including early ambulation and physical therapy, which were addressed by our intervention but not investigated in our study.

Another finding was the low rate of hemorrhage observed in our study despite the advanced age of the patients. This finding confirms safety results from previous studies that included large numbers of elderly patients. 

### Table 2. Pharmacologic and Mechanical Prophylaxis Use in Elderly Post–Acute Care Patients in the Preintervention and Postintervention Groups

<table>
<thead>
<tr>
<th>Prophylaxis</th>
<th>Preintervention (n = 709)</th>
<th>Postintervention (n = 664)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>High-risk dose of LMWH*</td>
<td>224 (31.6)</td>
<td>203 (30.6)</td>
<td>.68</td>
</tr>
<tr>
<td>Low-risk dose of LMWH†</td>
<td>175 (24.7)</td>
<td>123 (18.5)</td>
<td>.006</td>
</tr>
<tr>
<td>Unfractionated heparin</td>
<td>6 (0.8)</td>
<td>7 (1.0)</td>
<td>.69</td>
</tr>
<tr>
<td>Vitamin K antagonist</td>
<td>3 (0.4)</td>
<td>5 (0.7)</td>
<td>.49</td>
</tr>
<tr>
<td>Graduated compression stockings</td>
<td>194 (27.4)</td>
<td>230 (34.6)</td>
<td>.004</td>
</tr>
</tbody>
</table>

**Abbreviation:** LMWH, low-molecular-weight heparin.

*Prophylaxis with LMWH at high-risk dose included dalteparin sodium, 5000 U/d; enoxaparin sodium, 4000 U/d; nadroparin calcium sodium, 2580 U/d; and tinzaparin sodium, 4500 U/d.

†Prophylaxis with LMWH at low-risk dose, including dalteparin sodium, 2500 U/d; enoxaparin sodium, 2000 U/d; nadroparin calcium sodium, 1900 U/d; and reviparin sodium, 1432 U/d, was not recommended by the study guideline.
and supports the idea that physicians may often overestimate the risk for bleeding in their patients and inappropriately withhold pharmacologic prophylaxis.25

Our uncontrolled preintervention-postintervention study design has potential limitations. First, our intervention was not based on random assignment, and, therefore, our results may be confounded by other factors. Using the revised Wells rule, we showed that patients in the preintervention and postintervention groups were at comparable risk for DVT at hospital admission. Moreover, the decrease in the rate of DVT in the postintervention group remained significant after adjustment for risk factors in multivariable analysis. Although we cannot exclude hidden confounding factors, it was unlikely that they had more effect than our active multifaceted intervention. Second, a secular trend was unlikely to account for the decrease in DVT, inasmuch as several studies reported a striking upward trend in the rate of DVT previously or extend to the proximal veins.29 As a result, most DVTs start in the calf veins and may either resolve spontaneously or extend to the proximal veins.29 As a result, most DVTs,17 and published guidelines recommend treating patients with thrombosis confined to the deep veins of the calf with an anticoagulant agent for 3 months.30

In our study, the decrease in the rate of isolated distal DVT in patients in the postintervention group was parallel to the decrease in the rate of proximal DVT, for which the diagnostic performance of compression ultrasonography is poorer than for proximal clots.37 However, several studies reported much better diagnostic performance in patients with asymptomatic disease28 when compression ultrasonography was performed by staff with substantial experience in ultrasonography and using a standardized examination procedure, as in our study. Even if the lack of sensitivity of compression ultrasonography were real in our study, it would not explain the decreased OR of DVT in patients in the postintervention group because the same diagnosis procedure was used in the 2 study phases. Fourth, the clinical significance of isolated distal DVT is controversial, although distal and proximal DVTs are likely 2 manifestations of the same underlying disease. There is evidence that DVT usually starts in the calf veins and may either resolve spontaneously or extend to the proximal veins.29 As a result, most DVTs,17 and published guidelines recommend treating patients with thrombosis confined to the deep veins of the calf with an anticoagulant agent for 3 months.30

In our study, the decrease in the rate of isolated distal DVT in patients in the postintervention group was parallel to the decrease in the rate of proximal DVT, for which the diagnostic performance of compression ultrasonography is poorer than for proximal clots.37 However, several studies reported much better diagnostic perfor-
CONCLUSIONS

This multicenter study provides observational evidence that a multifaceted intervention directed at all medical providers can be followed by a decrease in DVT without compromising patient safety after acute care. More active strategies adapted to this setting should be developed and evaluated to enforce compliance with evidence-based guidelines.

Accepted for Publication: June 5, 2006.

Author Affiliations: Quality of Care Unit (Drs Seller and Labarere) and Department of Clinical Research (Dr Bosson), University Hospital, and ThEEMAS, TIMC-IMAG, National Center for Scientific Research (CNRS 5525), Joseph Fourier University (Drs Labarere and Bosson), Grenoble, France; Department of Functional Explorations, University Hospital, Caen, France (Drs Avray, Barrellier, and Le Hello); Department of Geriatrics, Charles-Foix Hospital, Assistance Publique des Hôpitaux de Paris, Ivry-sur-Seine, France (Dr Belmin); Department of Vascular Medicine, General Hospital, La Roche-sur-Yon, France (Dr Le Roux); and Department of Vascular Medicine, University Hospital, Amiens, France (Dr Sevestre).

Correspondence: Jose Labarere, MD, Quality of Care Unit, University Hospital, BP 217, 38043 Grenoble CEDEX 9, France (JLabarere@chu-grenoble.fr).


Group Participants: The following investigators and institutions in France participated to the study: Agen: L. Ahlinvi, MD; M. Saucaz-Larame, MD; and P. Lacoume, MD. Hospital Sud, Amiens: M. A. Sevestre, MD, MSc; I. Defouilloy, MD; J. Lienard, MD; A. Votte, MD; M. Duboisset, MD; F. Cressent, MD; J. F. Brault, MD; S. Dupas, MD; M. Caminzuoli, MD; and B. Tribout, MD. Saint-Victor, Amiens: D. Defrance, MD; and Y. Grumbach, MD. Amnecy: C. Bailly, MD; T. Berimilli, MD; F. Stedel, MD; O. Pichot, MD; L. Belle, MD; L. Michelli, MD; F. Picot, MD; and J. Sirot, MD. Arras: A. Rifai, MD; and V. Petit, MD. Auch: H. Paradis, MD; and M. Camallieres, MD. Belflay: I. Brikli, MD; M. Filali, MD; and M. Chuzel, MD, MSc. Bret: L. Bressollette, MD; B. Guisas, MD; and D. Leuzinger, MD. Betharam: M. Benoît, MD; L. Genuit-Leclerc, MD; D. Caraty, MD; B. James, MD; B. Yahloufi, MD; E. Gallet, MD; and F. Leverrier, RN. Caen: M.-T. Barrellier, MD; A. S. Delmas, MD; and C. Le Hello, MD. Carcassonne: L. Beysier-Weber, MD; and S. Cornée-Bertaud, MD. Dijon: B. Terriat, MD; F. Becker, MD, PhD; and A. Lalufraisse, MD. Châtillon-Grenoble: M. P. De-Angelis, MD; C. Bioteau, MD; J. L. Bosson, MD, PhD; P. Couturier, MD, PhD; M. Fontaine, MD; A. Franço, MD; S. Moine, MD; B. Satger, MD; L. Tranchant, MD; and J. Yver, MD. Chissée, Grenoble: P. Dubos, MD; and V. Mercier, MD. Pont Rouge 3, La Roche-sur-Yon: P. Le Roux, MD; P. Genay, MD; and P. Lermet, MD. Pont Rouge 4, La Roche-sur-Yon: F. Blanchet, MD; and J. Lebreton, MD. Pont Rouge 5, La Roche-sur-Yon: N. Aubry-Ratovondriaka, MD, L. J. P. Teston, MD; L. Chenu, MD; and M. Menouer, MD. Lyon: P. Bureau du Colombier, MD; and P. Haond, MD. Montluçon: M. Baietto, MD, and M. A. Vian, MD. Montpellier: J. P. Larroche, MD; I. Quere, MD, PhD; C. Jeandel, MD, PhD; and G. Boge, MD. Niort: C. Dolci, MD; J. Lucas, MD; and L. Bessou, MD. Orléans: C. Bazzi, MD; H. Bazzi, MD; and P. Berger, MD. Paimiers: A. Cadene, MD. Pont-l’Évêque: F. Leenaert, MD; N. Tichet-Hus, MD; and D. Dochier, MD. Reims: S. Martin, MD; E. Bertin, MD; and D. Malgrange, MD. Rodez: P. Carriere, MD; and J. P. Calmes, MD. Saint-Hilaire du Touvet: B. Villemur, MD. Servan: O. Aouad-Massiere, MD; and J. Belmin, MD, PhD. Purpan: Toulouse: M. Degelli, MD, and F. Nourhashemi, MD. Rangueil, Toulouse: P. Leger, MD; B. Fontan, MD; H. Boccalon, MD, PhD; A. Elias, MD; M. Elias, MD; and C. Lafont, MD. Val d’Auge: V. Bénard, MD. Versailles: J. M. Baud, MD; V. Donval, MD; and C. Ducruzet, MD.

Financial Disclosure: Drs Bosson and Sevestre served as consultants for Sanofi-Aventis France.

Funding/Support: This study was supported by a grant from the French Ministry of Health (Programme Hospitalier de Recherche Clinique) and by a grant from the Égide Foundation, Paris, France (Programme Lavoisier, French Foreign Office; Dr Labarere).

Acknowledgment: We thank Sonosite France for providing the ultrasound systems, and Corinne Frison, BA, for study management, Philippe Dupas, BSc, for logistic support, and Linda Northrup, PhD, for editorial assistance.

REFERENCES


